Information Provided By: 
Fly News Breaks for November 18, 2019
AIMT
Nov 18, 2019 | 05:42 EDT
Piper Jaffray analyst Christopher Raymond is "increasingly comfortable" with his bullish thesis on Aimmune Therapeutics after traveling with management. The analyst says he's "much more confident" that Palforzia's launch can meaningfully outperform expectations, both near- and long-term. When coupling this with the stock's 30% short interest, Raymond likes the opportunity for "meaningful" share upside into this drug's late January expected approval and launch. He keeps an Overweight rating on Aimmune with a $60 price target.
News For AIMT From the Last 2 Days
There are no results for your query AIMT
